Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMANKTO)

Drug Name
Vatreptacog alfa (activated) Drug Info
Synonyms NN-1731; NNC-0078-0000-0007; Recombinant factor VIIa analog with mutations V158D/E296V/M298Q (bleeding disorders), Novo Nordisk
Indication
Disease Entry ICD 11 Status REF
Bleeding disorder GA20-GA21 Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMANKTO

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Coagulation factor VII (F7) TTF0EGX FA7_HUMAN Modulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Coagulation factor VII (F7) DTT F7 9.218 4.853 5.6 5.747
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Bleeding disorder
ICD Disease Classification GA20-GA21
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Coagulation factor VII (F7) DTT F7 2.52E-01 -0.03 -0.19
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT01392547) Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors. U.S. National Institutes of Health.
2 Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9.